David E. Levy
Keine laufenden Positionen mehr
Profil
David E.
Levy was Vice President of Clinical Development for Neurobiological Technologies, Inc. from September 2004 to January 31, 2009.
From June 2003 to August 2004, he was International Project Team Leader at Eisai Medical Research, Inc. Previously, he was a Co-Founder of Empire Pharmaceuticals.
He served as an Advisor to Empire Pharmaceuticals and as Senior Director of Medical Research at DOV Pharmaceutical, Inc. From 1991 to 2001, Dr. Levy was employed with Knoll Pharmaceuticals, serving initially as Senior Director and Therapeutic Head of Clinical CNS and then as Senior Director of Cardiovascular/Internal Medicine.
He served as Executive Vice Chair of Neurology from 1988 to 1991 at Weill-Cornell Medical College and New York Presbyterian Hospital.
Dr. Levy is a Fellow of the American Academy of Neurology, the American College of Physicians and the Stroke Counsel of the American Heart Association.
He received a BA from Harvard College and an MD from Harvard Medical School.
Ehemalige bekannte Positionen von David E. Levy
| Unternehmen | Position | Ende |
|---|---|---|
| NEUROBIOLOGICAL TECHNOLOGIES, INC. | Technik-/Wissenschafts-/F&E-Leiter | 31.01.2009 |
| Eisai Medical Research, Inc. | Corporate Officer/Principal | 01.08.2004 |
| ABBOTT INDIA LIMITED | Corporate Officer/Principal | 01.01.2001 |
NewYork-Presbyterian Hospital
 NewYork-Presbyterian Hospital Hospital/Nursing ManagementHealth Services NewYork-Presbyterian Hospital offers healthcare services. Its services include surgery, corporate health, nephrology, dermatology, cardiology, hepatology, vascular care, emergency care, and ambulatory care. The company was founded in 1771 and is headquartered in New York, NY. | Corporate Officer/Principal | 01.01.1991 |
DOV Pharmaceutical, Inc.
 DOV Pharmaceutical, Inc. Miscellaneous Commercial ServicesCommercial Services DOV Pharmaceutical, Inc. discovers and develops novel drugs. It focuses on the development of novel product candidates for disorders of the central nervous system, or CNS. It have drug development programs that are at the preclinical, Phase I and Phase II clinical stages, including DOV 21,947 (in a Phase II clinical trial for depression), DOV 102,677 (which has completed a Phase I clinical trial) and a preclinical discovery program in reuptake inhibitors and GABA modulators. The company was founded by Arnold S. Lippa in May, 1995 and is headquartered in Somerset, NJ. | Technik-/Wissenschafts-/F&E-Leiter | - |
Ausbildung von David E. Levy
| Harvard University | Doctorate Degree |
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
| Börsennotierte Unternehmen | 2 |
|---|---|
| NEUROBIOLOGICAL TECHNOLOGIES, INC. | Health Technology |
| ABBOTT INDIA LIMITED | Health Technology |
| Private Unternehmen | 4 |
|---|---|
DOV Pharmaceutical, Inc.
DOV Pharmaceutical, Inc. Miscellaneous Commercial ServicesCommercial Services DOV Pharmaceutical, Inc. discovers and develops novel drugs. It focuses on the development of novel product candidates for disorders of the central nervous system, or CNS. It have drug development programs that are at the preclinical, Phase I and Phase II clinical stages, including DOV 21,947 (in a Phase II clinical trial for depression), DOV 102,677 (which has completed a Phase I clinical trial) and a preclinical discovery program in reuptake inhibitors and GABA modulators. The company was founded by Arnold S. Lippa in May, 1995 and is headquartered in Somerset, NJ. | Commercial Services |
NewYork-Presbyterian Hospital
NewYork-Presbyterian Hospital Hospital/Nursing ManagementHealth Services NewYork-Presbyterian Hospital offers healthcare services. Its services include surgery, corporate health, nephrology, dermatology, cardiology, hepatology, vascular care, emergency care, and ambulatory care. The company was founded in 1771 and is headquartered in New York, NY. | Health Services |
Empire Pharmaceuticals, Inc.
 Empire Pharmaceuticals, Inc. Miscellaneous Commercial ServicesCommercial Services Part of Neurobiological Technologies, Inc., Empire Pharmaceuticals, Inc. develops late-stage perfusion therapy for use in the treatment of acute ischemic stroke. The company is based in Newbury Park, CA. The company was founded by Stephen J. Petti, David E. Levy. Empire Pharmaceuticals was acquired by Neurobiological Technologies, Inc. on July 15, 2004 for $22.91 million. | Commercial Services |
| Eisai Medical Research, Inc. |